CP v2

Category: Psychology

  • Cutting Daily TV Time May Lower Depression Risk, With Middle Age Seeing the Biggest Gains

    Cutting Daily TV Time May Lower Depression Risk, With Middle Age Seeing the Biggest Gains

    Reducing time spent watching television and replacing it with more active or restorative habits may lower the risk of major depressive disorder, according to a new study published in European Psychiatry.

    The research suggests the strongest benefits appear in middle-aged adults, while effects are smaller or less consistent among younger and older groups.

    Unlike earlier studies that often linked sedentary behavior to poorer mental health in general, the new analysis focused on what happens when TV time is actively swapped for specific alternatives such as sports, sleep, or other daily activities.

    Lead author Rosa Palazuelos-González of the University of Groningen said the work helps clarify how reallocating screen time, rather than simply reducing it, could influence depression risk over time.

    What the researchers measured

    The study drew on Lifelines, a large Dutch population cohort that followed 65 454 adults who did not have depression at the start of the analysis.

    Participants were tracked for four years, reporting time spent watching TV, sleeping, doing household tasks, commuting, leisure activity, physical activity at work or school, and sports.

    Major depressive disorder was assessed using the Mini International Neuropsychiatric Interview, a structured diagnostic tool widely used in clinical and research settings.

    When researchers modeled a 60-minute shift away from TV toward other activities, they found an 11% lower likelihood of developing major depression across the overall sample.

    In scenarios where 90 or 120 minutes were reallocated, the estimated reduction in likelihood increased, reaching about 25.91% for larger shifts.

    Middle age stands out most

    The largest estimated improvements were seen in middle-aged adults, where replacing one hour of TV per day was associated with an 18.78% lower risk of developing depression.

    In that same age group, reallocating 90 minutes was linked to a 29% reduction, and replacing two hours corresponded to a 43% drop in risk.

    Most substitutions were associated with better outcomes, but swapping only 30 minutes of TV for household chores did not appear to meaningfully change risk.

    By contrast, replacing 30 minutes with sports was associated with an 18% reduction, the biggest improvement among the activities analyzed.

    Why age differences may matter

    Among older adults, the researchers did not find broad, statistically meaningful changes when TV time was redistributed, except when the replacement activity was sports.

    In that group, shifting 30 to 90 minutes from TV to sports was linked to modest decreases in depression probability.

    In younger adults, moving time away from TV toward physical activity did not significantly change depression risk in the models.

    The authors suggested this may be because younger participants tend to be more active overall, potentially already meeting thresholds where additional activity yields smaller mental health benefits.

    The findings do not prove that television causes depression, but they add evidence that how people spend discretionary time may matter, especially in midlife.

    For individuals looking to reduce risk, the results point toward practical substitutions, with sports and other movement-based activities showing the most consistent associations.

  • New brain-mapping study suggests psychedelics mute visual reality and amplify memory signals

    New brain-mapping study suggests psychedelics mute visual reality and amplify memory signals

    Psychedelic substances act on the brain by binding to serotonin receptors. Scientists have identified at least 14 different receptors that respond to the neurotransmitter serotonin. Psychedelics are especially drawn to one known as the 2A receptor. This receptor not only affects learning but also dampens activity in parts of the brain responsible for processing visual information.

    “We have observed in earlier studies that visual processes in the brain are suppressed by this receptor,” says Callum White, first author of the study. “This means that visual information about things happening in the outside world becomes less accessible to our consciousness. To fill this gap in the puzzle, our brain inserts fragments from memory — it hallucinates.”

    In other words, when incoming visual signals are reduced, the brain compensates by pulling stored images and experiences from memory. Those internally generated fragments can blend into perception, producing hallucinations.

    Slow Brain Waves Shift Perception Toward Memory

    The researchers also uncovered how this shift unfolds in real time. Psychedelics increase rhythmic patterns of brain activity, known as oscillations, in visual regions. Oscillations are coordinated waves of neural firing that help different parts of the brain communicate with each other.

    After psychedelics were administered, the team observed a rise in low-frequency (5-Hz) waves in visual areas. These slower waves stimulated another region called the retrosplenial cortex, a key hub involved in accessing stored memories. As this communication strengthens, the brain enters a different operating mode. Awareness of current external events becomes weaker, while perception relies more heavily on recalled information. As Professor Dirk Jancke, who led the study, describes it, the experience is “a bit like partial dreaming.”

    Real-Time Brain Imaging Reveals the Mechanism

    To capture these changes, the scientists used an advanced optical imaging technique that tracks neural activity across the entire surface of the brain in real time. The experiments relied on specially engineered mice created by Professor Thomas Knöpfel at Hong Kong Baptist University. These animals were designed to produce fluorescent proteins in specific types of brain cells.

    This approach allowed researchers to pinpoint the source of the signals they recorded. “We therefore know exactly in our experiments that the measured fluorescent signals originate from pyramidal cells of the cortical layers 2/3 and 5, which mediate communication within and between brain regions,” says Jancke. These cells play a central role in transmitting information across the cortex.

    Implications for Depression and Anxiety Treatment

    The findings may also help refine psychedelic-assisted therapy. Researchers believe that, under medical supervision, these substances can temporarily shift brain activity in ways that encourage the recall of positive memories and weaken deeply ingrained negative thought patterns.

    “When used under medical supervision, such substances can temporarily change the state of the brain to selectively recall positive memory content and restructure learned, excessively negative thought patterns, i.e., to be able to unlearn negative context. It will be exciting to see how such therapies are further personalized in the future,” says Jancke.

    By clarifying how psychedelics redirect perception from the outside world to internal memory networks, the study provides a clearer biological explanation for both hallucinations and the growing therapeutic potential of these compounds.

  • New study maps adolescent synapse hotspots, raising fresh questions about brain pruning and schizophrenia risk

    New study maps adolescent synapse hotspots, raising fresh questions about brain pruning and schizophrenia risk

    Researchers have identified previously overlooked synapse hotspots that form during adolescence, suggesting the teenage brain may actively build dense new connections alongside the well-known process of synaptic pruning. The findings, reported by Kyushu University scientists in Science Advances, add nuance to how neural circuits mature during a critical developmental window.

    Synapses are the communication points between neurons, and for decades a common model held that synapse numbers rise in childhood and then drop in adolescence as weaker links are removed. That pruning-focused framework has influenced theories of neuropsychiatric disorders, including the idea that excessive synapse loss could contribute to schizophrenia.

    The new work points to a more complex picture: localized bursts of synapse formation in specific parts of neurons. Using a tissue-clearing technique and super-resolution imaging, the team mapped dendritic spines across entire Layer 5 cortical neurons, which play a major role in integrating signals and producing cortical output.

    In young mice before weaning, dendritic spines were distributed more evenly along neurons. Between about three and eight weeks of age, the researchers observed a sharp rise in spine density in a single section of the apical dendrite, culminating in a tightly packed hotspot that was not present earlier.

    The authors argue this pattern means adolescent development is not defined solely by pruning, but also by targeted construction of new synaptic clusters. They also report that in mice carrying mutations in genes linked to schizophrenia risk, the hotspot did not develop normally because synapse formation during adolescence was reduced.

    While the results rely on mouse models and do not confirm the same mechanism in humans, they sharpen questions about which circuits are built during adolescence and how disruptions might alter brain function. The researchers say the next step is to identify the brain regions and inputs driving these newly formed connections during the adolescent period.

  • Vagus nerve stimulation implant shows lasting gains for treatment-resistant depression, and some patients reach remission

    Vagus nerve stimulation implant shows lasting gains for treatment-resistant depression, and some patients reach remission

    About one in five adults in the United States will experience major depression at some point in their lives. Many people improve after trying a few treatments, but for as many as one-third of patients, standard antidepressants or psychotherapy do not provide enough relief. This condition, known as treatment-resistant depression, can persist for years or even decades. New research now suggests that a small implanted device may offer meaningful and long-lasting improvement for people with the most severe forms of the illness.

    Scientists at Washington University School of Medicine in St. Louis led a large, multicenter clinical trial to evaluate this approach. The researchers found that a device designed to stimulate the vagus nerve was linked to sustained improvements in depressive symptoms, daily functioning, and overall quality of life. For most patients who showed improvement after one year, those gains continued for at least two years.

    The participants in the study had lived with depression for an average of 29 years and had already tried about 13 treatments without success. These included intensive options such as electroconvulsive therapy and transcranial magnetic stimulation, highlighting just how difficult their condition had been to treat.

    The latest results come from the ongoing RECOVER trial and were published Jan. 13 in the International Journal of Neuropsychopharmacology.

    “We believe the sample in this trial represents the sickest treatment-resistant depressed patient sample ever studied in a clinical trial,” said lead author Charles Conway, MD, a professor of psychiatry and director of the WashU Medicine Treatment Resistant Mood Disorders Center. “There is a dire need to find effective treatments for these patients, who often have no other options. With this kind of chronic, disabling illness, even a partial response to treatment is life-altering, and with vagus nerve stimulation we’re seeing that benefit is lasting.”

    How vagus nerve stimulation works

    The RECOVER study was designed to test whether adding vagus nerve stimulation (VNS) to ongoing care could improve outcomes for people with treatment-resistant depression. The therapy involves surgically placing a device under the skin in the chest. The device sends carefully controlled electrical signals to the left vagus nerve — a key communication pathway between the brain and many internal organs.

    The VNS Therapy System is made by LivaNova USA, Inc., which sponsored and funded the RECOVER trial. The study is collecting long-term data on mood, daily function, and quality of life in people with severe treatment-resistant depression. One aim of the research is to help the U.S. Centers for Medicare and Medicaid Services (CMS) decide whether to expand coverage for the therapy. Because many private insurers follow CMS decisions, approval could make the treatment accessible to far more patients, as cost has been a major barrier.

    Inside the RECOVER trial

    Nearly 500 patients were enrolled across 84 locations in the United States. About three-quarters of participants were so severely affected by depression that they were unable to work. All patients received the implanted device, but only half had the device activated during the first year to allow for comparison. Researchers tracked changes in depression severity, quality of life, and everyday functioning.

    A response was considered meaningful if symptoms improved by at least 30% compared with the start of the study. A reduction of 50% or more was classified as a “substantial” response.

    Conway emphasized that even modest improvements can dramatically change a person’s life. Severe depression can leave people feeling “paralyzed by life,” unable to manage basic daily activities and at higher risk of hospitalization or early death.

    Earlier findings from the blinded first year of the trial showed that patients with activated devices spent more time with improved mood, better functioning, and higher quality of life than those whose devices were not active. However, the primary measurement tool (the Montgomery-Åsberg depression scale, which measures the severity of depressive episodes) did not show a statistically significant difference between the two groups.

    Benefits that last over time

    In the newest analysis, the researchers focused on patients whose devices were active from the start of the trial. They wanted to see whether improvements seen at 12 months would continue through 24 months. They also examined whether some patients who did not improve in the first year might respond later with continued treatment.

    Out of 214 patients who received active treatment from the beginning, about 69%, or 147 people, showed a meaningful response at one year in at least one outcome measure. Among those who benefited at 12 months, more than 80% maintained or improved their results by the two-year mark across measures of depression, quality of life, and daily functioning. For patients with a substantial response at one year — defined as at least a 50% reduction in symptoms — 92% were still benefiting at two years.

    Nearly one-third of participants who had not improved after the first year reported benefits by the end of the second year, suggesting that the therapy may take longer to work for some individuals. Relapse rates remained low among those who responded, particularly among the strongest responders.

    The researchers also found that more than 20% of treated patients, or 39 people, were in remission after 24 months. This means their symptoms had eased enough for them to function normally in daily life, a result Conway described as especially notable.

    “We were shocked that one in five patients was effectively without depressive symptoms at the end of two years,” he said. “Seeing results like that for this complicated illness makes me optimistic about the future of this treatment. These results are highly atypical, as most studies of markedly treatment-resistant depression have very poor sustainability of benefit, certainly not at two years. We’re seeing people getting better and staying better.”

    Funding and disclosures

    The study was supported by LivaNova, PLC, the developer and manufacturer of the Vagus Nerve Stimulation therapy system. LivaNova, PLC supported the study design, data analysis, and preparation of the report. The U.S. Centers for Medicare & Medicaid Services approved the study under its NCD VNS for Treatment Resistant Depression. The authors alone made the final decision on the manuscript content and its submission for publication.

    Conway has received research support from the American Foundation for Suicide Prevention, Assurex Health, August Busch IV Foundation, Barnes-Jewish Hospital Foundation, LivaNova, National Institute of Mental Health, and the Taylor Family Institute for Innovative Psychiatric Research. He has also served as a consultant for LivaNova.

  • Schizophrenia study suggests brain prediction errors may drive hearing voices, and hints at an EEG biomarker

    Schizophrenia study suggests brain prediction errors may drive hearing voices, and hints at an EEG biomarker

    Researchers at UNSW Sydney say they have found some of the clearest evidence yet that auditory verbal hallucinations in schizophrenia may stem from a breakdown in how the brain recognizes its own inner speech. The team argues the brain may mislabel self-generated thoughts as if they were external voices.

    The study, published in Schizophrenia Bulletin, focuses on a well-known theory in psychiatry: that hallucinated voices can arise when the brain’s normal system for predicting the sound of one’s own speech fails. If that prediction signal misfires, activity in sound-processing regions may look more like the brain is hearing someone else.

    How inner speech is measured

    Because inner speech is private, testing it directly has long been difficult. The researchers used EEG recordings to track brain responses while participants silently imagined speaking simple syllables while hearing sounds through headphones.

    In everyday speech, the brain typically dampens activity in the auditory cortex because it anticipates the sensory consequences of one’s own voice. The new work examined whether that suppression effect also appears during imagined speech, and whether it differs in people who hear voices.

    What the EEG signals showed

    The experiment compared 55 people with schizophrenia spectrum disorders who had experienced auditory hallucinations within the previous week, 44 people with schizophrenia without recent hallucinations, and 43 healthy participants. During the task, participants imagined saying “bah” or “bih” while the same sounds were sometimes played aloud, without advance notice of a match.

    Healthy participants showed reduced brain responses when the imagined syllable matched the sound they heard, consistent with accurate prediction and sensory suppression. By contrast, people with recent hallucinations showed the opposite pattern, with stronger responses when the imagined and heard sounds matched.

    Participants with schizophrenia who had not recently heard voices showed responses between the other two groups. The authors say that gradient could indicate a link between the disrupted prediction mechanism and the current presence of hallucinations, rather than diagnosis alone.

    Could this become a biomarker?

    The team says the findings strengthen the case that some hallucinated voices feel real because the brain processes inner speech as if it were coming from outside. They also argue the EEG signature could eventually contribute to a biomarker approach, an area where schizophrenia still lacks definitive lab or imaging tests.

    Next, the researchers plan to test whether this response pattern can help identify people at elevated risk of psychosis before symptoms fully emerge. Earlier identification could support earlier intervention, although the authors note further validation is needed across broader populations and clinical settings.

  • EEG brain signals may offer a noninvasive path to restoring movement after spinal cord injury

    EEG brain signals may offer a noninvasive path to restoring movement after spinal cord injury

    Researchers are moving closer to a noninvasive way to help people with spinal cord injuries regain movement by decoding brain waves linked to intended actions. The approach centers on electroencephalography, or EEG, which records electrical activity from the scalp.

    In many spinal cord injuries, the brain can still generate normal movement commands, but damaged pathways prevent those signals from reaching muscles. That gap has driven efforts to build new routes for communication rather than repairing the spinal cord itself.

    A bid to avoid brain surgery

    A study published in APL Bioengineering by scientists in Italy and Switzerland examined whether EEG can reliably capture signals produced when patients attempt to move paralyzed limbs. The long-term goal is to translate those signals into commands that could drive assistive devices or stimulation therapies.

    Much of the earlier progress in brain-computer interfaces has relied on implanted electrodes that record activity directly from the brain. While implants can provide clearer signals, they also bring surgical risk and ongoing concerns such as infection and device complications.

    Why legs are harder to decode

    EEG is safer and easier to repeat, but it faces a fundamental limitation: signals recorded at the scalp are weaker and less precise than those captured inside the skull. This makes it difficult to pinpoint activity from deeper brain regions involved in movement control.

    The researchers noted that decoding attempts to move the legs can be especially challenging, because lower-limb control is represented more centrally in the brain. By contrast, signals for hand and arm movements are often easier to separate with surface recordings.

    Machine learning shows early promise

    To interpret the EEG patterns, the team used machine learning designed to work with small, complex datasets typical of clinical research. Patients wore an EEG cap and were asked to attempt simple movements while the system learned patterns associated with effort versus rest.

    The method could distinguish when a participant was trying to move versus staying still, but it struggled to reliably differentiate among specific movement types. The next step is improving classification so intended actions like standing or walking can be identified more consistently.

    Researchers say success would likely depend on better algorithms, improved EEG hardware, and careful integration with downstream technologies such as stimulators or external assistive systems. For patients, the appeal is clear: a potential route toward meaningful function without placing electrodes in the brain.

  • Study finds long COVID brain fog is reported far more in the U.S., raising questions about care and stigma

    Study finds long COVID brain fog is reported far more in the U.S., raising questions about care and stigma

    An international study comparing long COVID patients across four countries found that people treated in the United States reported markedly higher rates of brain fog and mental health symptoms than patients in India, Nigeria, or Colombia.

    Researchers say the gap is unlikely to be explained by biology alone and may instead reflect differences in culture, stigma, and access to diagnosis and follow-up care.

    The analysis tracked more than 3 100 adults with persistent neurological symptoms after COVID-19 who were evaluated at academic medical centers in Chicago, Medellín, Lagos, and Jaipur.

    Most participants were not hospitalized during their initial infection, allowing researchers to focus on long-term symptoms among people who experienced milder acute illness.

    Brain fog reports varied sharply

    Among non-hospitalized participants, 86% of U.S. patients reported brain fog, compared with 63% in Nigeria, 62% in Colombia, and 15% in India.

    Patterns for depression and anxiety were similarly uneven, with nearly three-quarters of non-hospitalized U.S. patients reporting these symptoms, far above rates reported at other sites.

    Investigators cautioned that higher reported symptom rates do not necessarily mean Americans have more severe disease.

    They argue that patients in some settings may be less likely to label cognitive problems as a medical issue or may have fewer opportunities to be screened and treated.

    Culture and healthcare access may matter

    Senior author Dr. Igor Koralnik of Northwestern University said it is more culturally accepted in the U.S. and Colombia to discuss mental health and cognitive changes.

    He added that stigma, health literacy, and limited availability of mental health providers could reduce reporting in other countries, masking the true burden.

    Across all regions, commonly reported neurological complaints included fatigue, headache, dizziness, muscle pain, sleep problems, and sensory disturbances such as numbness or tingling.

    The team said the findings underscore the need for culturally sensitive screening tools and more consistent long COVID follow-up, especially where care is harder to access.

    The study was published in Frontiers in Human Neuroscience and adds to growing evidence that long COVID can disrupt daily function and work capacity long after infection.

    Researchers involved in the project are also testing cognitive rehabilitation approaches for long COVID brain fog in partner sites, using shared protocols to compare outcomes.

  • Researchers move closer to an early Parkinson’s blood test, with a five-year timeline in sight

    Researchers move closer to an early Parkinson’s blood test, with a five-year timeline in sight

    Scientists in Sweden and Norway say they have identified early biological signals of Parkinson’s disease that can be detected in blood, potentially years before the hallmark movement symptoms appear. The work points to a narrow early window when the disease may be easier to spot and, in the long run, easier to target with treatments.

    The study, led by researchers at Chalmers University of Technology with collaborators at Oslo University Hospital, focuses on changes linked to DNA repair and cellular stress response. These processes appear to leave short-lived traces in blood during the prodromal phase, when brain damage is still limited.

    Why early detection is difficult

    Parkinson’s affects more than 10 million people worldwide, and prevalence is expected to rise sharply as populations age. Yet most diagnoses still come after motor symptoms begin, when substantial loss of dopamine-producing nerve cells has often already occurred.

    Because the disease can develop gradually over many years, researchers have been searching for practical screening tools that work before disability sets in. Approaches such as brain imaging and cerebrospinal fluid testing can be informative, but they are harder to use broadly for early screening than a routine blood draw.

    Machine learning spots a distinct signature

    Using advanced analytics, including machine learning, the team reported a pattern of gene activity tied to DNA repair and stress response that appeared in people at an early stage of Parkinson’s. The same pattern was not observed in healthy controls or in patients with established motor symptoms, suggesting it may be time-sensitive.

    The researchers argue that this time-limited signal could be useful in identifying people at risk before tremor, rigidity, or slowed movement become obvious. They also say the biology behind the signature could help guide the search for therapies, including evaluating existing drugs for repurposing.

    What comes next for a blood test

    The team says the next steps include validating the findings in additional patient groups and refining tools to measure the signature reliably in clinical settings. They estimate that blood tests based on this approach could begin to be trialed in healthcare within about five years, though broader rollout would depend on further evidence.

    Experts generally caution that promising biomarkers must clear major hurdles, including accuracy across diverse populations and the ability to distinguish Parkinson’s from other neurodegenerative conditions. Still, a scalable blood test remains one of the most sought-after developments in Parkinson’s research because it could enable earlier monitoring and, eventually, earlier intervention.

    The findings were published in npj Parkinson’s Disease, and the research was supported by several funders, including the Michael J. Fox Foundation and national research bodies in Sweden and Norway. If confirmed, the work could add momentum to the global push for practical biomarkers that shift Parkinson’s care toward prevention and earlier treatment decisions.

  • Why US Midlife Is Getting Harder: Rising Loneliness, Memory Decline, and a Weaker Safety Net

    Why US Midlife Is Getting Harder: Rising Loneliness, Memory Decline, and a Weaker Safety Net

    Middle age is increasingly emerging as a pressure point in the United States, with Americans born in the 1960s and early 1970s reporting more loneliness and depression than earlier generations. Researchers also see declines in episodic memory and physical strength that appear more pronounced than in many other high-income countries.

    The pattern was outlined in cross-national research led by Arizona State University psychologist Frank J. Infurna, which compared survey data across 17 countries. The analysis suggests the US is diverging from peers where midlife health and well-being have generally improved over recent decades.

    Why the US stands out

    A key difference identified by the researchers is the level of public support for families. Many European countries expanded family benefits since the early 2000s, while US spending on comparable supports has been far more limited.

    That gap matters during midlife, when many people are simultaneously managing full-time work, raising children, and helping aging parents. In countries with stronger benefits, midlife loneliness tended to be lower and rose more slowly over time.

    Healthcare costs and financial strain

    Healthcare affordability also appears to play a central role in the US midlife squeeze. Even as the United States spends more per person on healthcare than other wealthy nations, individuals often face higher out-of-pocket costs and more financial exposure.

    The research links these pressures to delayed or skipped care, reduced preventive visits, and higher stress from medical bills and debt. Those dynamics can compound other midlife burdens, including work instability and caregiving responsibilities.

    When education protects less

    Income inequality was another factor associated with worse midlife outcomes, aligning with broader evidence that inequality can weaken health and social ties. The researchers noted that inequality has risen in the United States since the early 2000s, while it has been steadier in much of Europe.

    One of the more striking findings is cognitive: despite higher educational attainment over time, US middle-aged adults showed declines in episodic memory not widely seen in peer countries. The authors suggest chronic stress, financial insecurity, and cardiovascular risk factors may be eroding the protective effect education once provided.

    The study argues these trends are not inevitable, pointing to personal buffers such as stronger social connections and a sense of control over daily life. But it also concludes that policy choices, including paid leave, childcare support and more affordable access to care, are closely tied to how well midlife populations fare.

  • Reelin protein study hints at new way to strengthen leaky gut and reduce depression symptoms

    Reelin protein study hints at new way to strengthen leaky gut and reduce depression symptoms

    Researchers at the University of Victoria in Canada say a naturally occurring protein called Reelin may help explain how chronic stress can affect both the gut and the brain. Their findings, published in the journal Chronic Stress, point to Reelin as a potential target for future treatments aimed at gut barrier damage and depression-related symptoms.

    The study focuses on the gut barrier, the lining that controls what passes from the intestines into the bloodstream. Under prolonged stress, that barrier can become more permeable, a process often described as leaky gut, which may allow bacterial components to enter circulation and trigger immune inflammation.

    How stress may lower Reelin

    In preclinical experiments, the team observed that chronic stress was associated with reduced Reelin levels in intestinal tissue. When researchers administered a single small dose of Reelin, levels in the intestine returned to what the scientists described as normal ranges in their model.

    The authors argue the result matters because gut inflammation is increasingly studied as a contributor to mood disorders through the gut-brain axis. In this framework, immune signals and inflammatory processes can influence brain function, potentially worsening depression in vulnerable people.

    Why the gut-brain link matters

    Previous research has reported lower Reelin levels in brain tissue among people diagnosed with major depressive disorder, and similar patterns have been seen in stressed animal models. In earlier preclinical work cited by the team, Reelin administration was linked with antidepressant-like effects, though this does not yet demonstrate clinical benefit in humans.

    The researchers also highlight that the intestinal lining typically renews rapidly, roughly every few days, to maintain an effective barrier. They suggest Reelin may support this renewal process, which could help prevent barrier breakdown and reduce inflammation-driven effects that can intersect with depression.

    What comes next for Reelin research?

    Scientists caution that translating these findings into a therapy would require extensive follow-up, including safety studies, dosing work, and eventually human clinical trials. For now, the study adds to growing evidence that treating depression may, in some cases, involve addressing biological processes outside the brain, including gut integrity and immune activation.

    The research was supported by funding from Canada’s federal granting agencies, including the Canadian Institutes of Health Research and the Natural Sciences and Engineering Research Council of Canada. The authors say further studies will be needed to clarify how Reelin works across tissues and whether it can be developed into a practical medical intervention.